Literature DB >> 24327306

Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma.

Carl Ludwig Behnes1, Felix Bremmer, Bernhard Hemmerlein, Arne Strauss, Philipp Ströbel, Heinz-Joachim Radzun.   

Abstract

Tumor-associated macrophages (TAMs) play a key role in cancer development. Especially, the immunosuppressive M2 phenotype is associated with increased tumor growth, invasiveness and metastasis. The differentiation of macrophages to the alternative phenotype M2 is mediated, inter alia, by macrophage colony-stimulating factor (M-CSF). Papillary renal cell carcinoma (RCC) represents a rare tumor type which, based upon histological criteria, can be subdivided into two subtypes (I and II), of which type II is associated with poor prognosis. In both subtypes, typically, a dense infiltrate of macrophages is found. In the present study, the expression of CD68, CD163, M-CSF, Ki-67, and CD31 was examined in 30 type I and 30 type II papillary RCCs (n = 60). Both types of papillary RCCs contained an equally dense infiltrate of CD68-positive macrophages. Nearly all macrophages in papillary RCC type II expressed CD163, a characteristic for M2 macrophages. In type I papillary RCC, less than 30 % of macrophages expressed CD163. Furthermore, tumor cells in type II papillary RCC expressed significantly more M-CSF and showed increased (Ki-67 expression defined) proliferative activity in comparison with type I papillary RCC. In addition, the (CD31 defined) capillary density was higher in type II than in type I papillary RCC. A dense infiltrate of M2 phenotype TAM and high M-CSF expression in tumor cells are key features of type II papillary RCC. These findings might explain why the prognosis of papillary RCC type II is worse than that of type I.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24327306     DOI: 10.1007/s00428-013-1523-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  42 in total

Review 1.  The many faces of macrophage activation.

Authors:  David M Mosser
Journal:  J Leukoc Biol       Date:  2003-02       Impact factor: 4.962

2.  Tumor-associated macrophages: the double-edged sword in cancer progression.

Authors:  Jeremy J W Chen; Yi-Chen Lin; Pei-Li Yao; Ang Yuan; Hsang-Yu Chen; Chia-Tung Shun; Meng-Feng Tsai; Chun-Houh Chen; Pan-Chyr Yang
Journal:  J Clin Oncol       Date:  2004-12-14       Impact factor: 44.544

3.  Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head.

Authors:  Kiyoshi Yoshikawa; Shuichi Mitsunaga; Taira Kinoshita; Masaru Konishi; Shinichiro Takahashi; Naoto Gotohda; Yuichiro Kato; Masaki Aizawa; Atsushi Ochiai
Journal:  Cancer Sci       Date:  2012-10-04       Impact factor: 6.716

Review 4.  Distinct role of macrophages in different tumor microenvironments.

Authors:  Claire E Lewis; Jeffrey W Pollard
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

Review 5.  Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications.

Authors:  Michele De Palma; Craig Murdoch; Mary Anna Venneri; Luigi Naldini; Claire E Lewis
Journal:  Trends Immunol       Date:  2007-11-05       Impact factor: 16.687

6.  Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis.

Authors:  S M Scholl; C Pallud; F Beuvon; K Hacene; E R Stanley; L Rohrschneider; R Tang; P Pouillart; R Lidereau
Journal:  J Natl Cancer Inst       Date:  1994-01-19       Impact factor: 13.506

7.  Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma.

Authors:  Toni Valković; Frane Dobrila; Mauro Melato; Franco Sasso; Clara Rizzardi; Nives Jonjić
Journal:  Virchows Arch       Date:  2001-05-16       Impact factor: 4.064

8.  Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma.

Authors:  Yohei Mano; Shinichi Aishima; Nobuhiro Fujita; Yuki Tanaka; Yuichiro Kubo; Takashi Motomura; Akinobu Taketomi; Ken Shirabe; Yoshihiko Maehara; Yoshinao Oda
Journal:  Pathobiology       Date:  2013-01-25       Impact factor: 4.342

9.  The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.

Authors:  H O Smith; P S Anderson; D Y Kuo; G L Goldberg; C L DeVictoria; C A Boocock; J G Jones; C D Runowicz; E R Stanley; J W Pollard
Journal:  Clin Cancer Res       Date:  1995-03       Impact factor: 12.531

Review 10.  CSF-1 and its receptor in ovarian, endometrial and breast cancer.

Authors:  B M Kacinski
Journal:  Ann Med       Date:  1995-02       Impact factor: 4.709

View more
  26 in total

Review 1.  [History and perspectives of the monocyte-macrophage system].

Authors:  H-J Radzun
Journal:  Pathologe       Date:  2015-09       Impact factor: 1.011

2.  Upregulation of CSF-1 is correlated with elevated TAM infiltration and poor prognosis in oral squamous cell carcinoma.

Authors:  Xiao-Yu Guo; Jia-Yi Zhang; Xin-Zhan Shi; Qiong Wang; Wei-Li Shen; Wei-Wen Zhu; Lai-Kui Liu
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

Review 3.  Macrophage colony-stimulating factor and cancer: a review.

Authors:  S Chockalingam; Siddhartha Sankar Ghosh
Journal:  Tumour Biol       Date:  2014-09-20

4.  High expression of Twist is associated with tumor aggressiveness and poor prognosis in patients with renal cell carcinoma.

Authors:  Kojiro Ohba; Yasuyoshi Miyata; Tomohiro Matsuo; Akihiro Asai; Kensuke Mitsunari; Yohei Shida; Shigeru Kanda; Hideki Sakai
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

5.  Interactions between colon cancer cells and tumor-infiltrated macrophages depending on cancer cell-derived colony stimulating factor 1.

Authors:  Huayang Wang; Qianqian Shao; Jintang Sun; Chao Ma; Wenjuan Gao; Qingjie Wang; Lei Zhao; Xun Qu
Journal:  Oncoimmunology       Date:  2016-01-04       Impact factor: 8.110

6.  Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma.

Authors:  Liu Yang; Qian Wu; Le Xu; Weijuan Zhang; Yu Zhu; Haiou Liu; Jiejie Xu; Jianxin Gu
Journal:  BMC Cancer       Date:  2015-02-18       Impact factor: 4.430

7.  microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma.

Authors:  Zong-Tao Chai; Xiao-Dong Zhu; Jian-Yang Ao; Wen-Quan Wang; Dong-Mei Gao; Jian Kong; Ning Zhang; Yuan-Yuan Zhang; Bo-Gen Ye; De-Ning Ma; Hao Cai; Hui-Chuan Sun
Journal:  J Hematol Oncol       Date:  2015-05-29       Impact factor: 17.388

Review 8.  Drug Trafficking into Macrophages via the Endocytotic Receptor CD163.

Authors:  Jonas Heilskov Graversen; Søren Kragh Moestrup
Journal:  Membranes (Basel)       Date:  2015-06-23

9.  Difference in distribution profiles between CD163+ tumor-associated macrophages and S100+ dendritic cells in thymic epithelial tumors.

Authors:  Mutsuko Omatsu; Toshiaki Kunimura; Tetsuya Mikogami; Akira Shiokawa; Tomoko Nagai; Atsuko Masunaga; Akihiko Kitami; Takashi Suzuki; Mitsutaka Kadokura
Journal:  Diagn Pathol       Date:  2014-12-14       Impact factor: 2.644

10.  Experimental research of host macrophage canceration induced by glioma stem progenitor cells.

Authors:  Aidong Wang; Xingliang Dai; Baoqian Cui; Xifeng Fei; Yanming Chen; Jinshi Zhang; Quanbin Zhang; Yaodong Zhao; Zhimin Wang; Hua Chen; Qing Lan; Jun Dong; Qiang Huang
Journal:  Mol Med Rep       Date:  2014-12-02       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.